The cash provides a multi-year runway for therapeutic R&D, but the loss of LCT's revenue stream means ISCO is now effectively a pre-revenue biotech. Monitor for pipeline catalysts and potential use of cash for acquisitions or further restructuring. The escrow releases over the next 9 months could provide additional liquidity.
Price Chart
Executive Summary
International Stem Cell Corporation completed the sale of its wholly-owned subsidiary Lifeline Cell Technology (LCT) to ATCC for an adjusted purchase price of $25.25 million, receiving net cash proceeds of $21.69 million at closing. The disposition transforms ISCO into a much smaller entity focused on its remaining Lifeline Skin Care subsidiary and therapeutic R&D, with pro forma H1 2026 revenue collapsing from $4.99 million to $296,000 and net loss from continuing operations widening to $1.62 million.
Key Facts
- Adjusted purchase price of $25,250,000 (base $25M + $250K fixed add-back)
- Net cash received at closing: $21,688,000
- Escrow receivable of $2,600,000 (current asset, released over 6-9 months)
- Estimated pre-tax gain on sale: $22,174,000
- After-tax gain of $21,916,000 credited to accumulated deficit
- Pro forma cash balance jumps from $1,089,000 to $22,777,000
- Pro forma H1 2026 revenue drops to $296,000 from $4,990,000 historical
- Pro forma H1 2026 net loss from continuing operations: $1,616,000 vs historical $291,000
- ISCO retains Lifeline Skin Care and therapeutic R&D operations
- Related party note payable of $3,257,000 and Series D preferred stock of $4,300,000 remain
Financial Impact
Net cash infusion of $21.7M transforms balance sheet from negative equity (-$4.2M) to positive equity ($17.7M), but ongoing revenue base shrinks by ~94% and operating losses increase significantly.
Risk Factors
- Ongoing operating losses with minimal revenue base may require further dilution or debt
- Related party note payable of $3.26M and Series D preferred stock of $4.3M create financial obligations
- Transition services agreement income deemed immaterial — no near-term revenue offset
- Post-closing working capital true-up could adjust gain and cash received
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007007 |
| Document: intlstemcell_8k.htm | 0001683168-26-007007 |
| Document: 0001683168-26-007007-index-headers.html | 0001683168-26-007007 |
| Document: 0001683168-26-007007-index.html | 0001683168-26-007007 |
| Document: 0001683168-26-007007.txt | 0001683168-26-007007 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | 144 | $0.3600 | awaiting T+60 | — | $0.1400 (−61.11%) |
Sep 8, 2026 6w ago | 8-K | $0.3700 | awaiting T+60 | — | $0.1400 (−62.16%) |
Jul 15, 2026 14w ago | 8-K | $0.2100 $0.2800 | ▲ +33.33% | ▲ +29.37% | $0.1400 (−33.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers